Clinical Trial Agreement (CTA)

Examples

Worked examples

Is an instance
Illustrative, composite example: for an industry-sponsored, multi-site Phase III oncology trial, the CTA between the sponsor and an academic medical center sets a per-subject payment schedule tied to visit completion plus separate milestone payments for site activation and database lock; obligates the sponsor to indemnify the institution and investigators for claims arising from the investigational product or protocol design (consistent with ICH E6 Section 3.14/5.8's approach to sponsor compensation for trial-related injury), carved out where the institution's own negligence or a protocol deviation caused the harm; assigns background IP to whichever party brought it in and foreground IP arising from the sponsor's product to the sponsor, while granting the institution a right to publish results after a defined sponsor confidentiality-review period (commonly on the order of 30-90 days, sometimes extended if the sponsor needs to file a patent application); and is negotiated on the institution's side by its Clinical Trials Office rather than by the investigator directly.
Is an instance
Illustrative, composite example: for an investigator-initiated trial (IIT) where the academic institution itself holds the IND and acts as sponsor, the CTA with a commercial entity supplying study drug at no cost looks structurally different -- there is little or no per-subject payment flowing from the drug supplier to the institution, the institution (as sponsor) carries its own trial insurance and indemnification obligations toward its investigators and subjects rather than receiving indemnification from a commercial sponsor, and the agreement is often shorter, centered mainly on drug-supply terms, safety-reporting obligations back to the supplier, and publication rights, rather than a full commercial-sponsor budget and indemnification package.

Counter-examples

Looks similar, but isn't

Not an instance
A Material Transfer Agreement (MTA) is not a CTA: an MTA governs the transfer of a specific biological material, reagent, or research tool between institutions and the terms under which it may be used, and can exist entirely independent of any clinical trial (e.g., a cell line shared for basic-science research); it does not set trial budget, indemnification, or publication terms for conducting a study on human subjects.
Not an instance
The informed consent form (ICF) is not a CTA: the ICF is the participant-facing disclosure document reviewed by the IRB that explains a trial's risks, benefits, and (per 45 CFR 46.116 in the US) whether compensation or treatment is available if a subject is injured -- it is downstream of, and must stay consistent with, the CTA's institution-facing indemnification and insurance terms, but it is not itself a contract between the sponsor and the institution and does not set payment, IP, or publication terms.

Editorial commentary

A Clinical Trial Agreement (CTA) is the contract that makes a clinical trial financially and legally executable at a given site. It sits alongside — but is legally distinct from — the protocol (what will be done scientifically) and the informed consent form (what participants are told and agree to). The CTA is negotiated between the sponsor (or a Contract Research Organization acting on the sponsor’s behalf) and the participating institution, typically with the Principal Investigator as a named party or signatory.

What a CTA Actually Governs

Regardless of institution or sponsor, a CTA typically addresses the same core set of business and risk-allocation questions:

Budget and payment terms — the per-subject fee schedule, milestone payments (site activation, first patient in, database lock), invoicing cadence, and what happens to payment obligations if a subject withdraws partway through the visit schedule.
Indemnification and insurance — which party covers claims arising from the investigational product, protocol design, or a party’s own negligence. ICH E6(R2) Section 5.8, renumbered to Section 3.14 (“Insurance/Indemnification/Compensation to Participants and Investigators”) in the finalized ICH E6(R3), is the regulatory anchor most CTA indemnification language is written against: where required by applicable regulation, the sponsor should provide insurance or indemnify the institution/investigator against trial-related claims, except claims arising from the institution’s own malpractice or negligence. Industry sources describe indemnification as the most heavily negotiated section of virtually every CTA — for a full walkthrough of how these clauses are typically structured and where negotiation friction concentrates, see Clinical Trial Indemnity and Insurance: What CTAs Actually Cover.
Subject-injury coverage — closely related to indemnification but worth naming separately: the CTA’s institution-facing commitment on who pays for treatment of a trial-related injury must stay consistent with what the ICF discloses to the participant under 45 CFR 46.116 (or the equivalent EU Clinical Trials Regulation Article 76 requirement for member states to ensure a compensation mechanism is in place).
Intellectual property ownership — allocation of background IP (what each party brought into the relationship) versus foreground IP (what’s newly created during the trial), typically following the same background/foreground logic used in sponsored-research agreements generally.
Publication and disclosure rights — the institution’s and investigator’s right to publish trial results, subject to a defined sponsor confidentiality-review window (commonly in the 30-90 day range, sometimes extended if the sponsor needs to file a patent application), with most institutional policies capping total delay and prohibiting indefinite suppression.
Data ownership and confidentiality — who owns the trial dataset, what the institution may retain and use for its own research after the trial closes, and confidentiality obligations around the sponsor’s proprietary protocol and product information.
Regulatory-compliance representations, term, termination, and record retention — each party’s representations about IRB approval and GCP compliance, conditions under which either party can terminate, and how long trial records must be retained after closeout.

A Structural Note, Not a Template

CTA language varies substantially by sponsor, institution, trial phase, and jurisdiction — far more than a document like a budget justification or a standard software license agreement, where the underlying structure is comparatively uniform. Many institutions are also subject to constraints that shape their CTA position regardless of what a sponsor’s standard template asks for: public/state universities and state-affiliated academic medical centers are frequently barred by sovereign-immunity and public-funds statutes from indemnifying a sponsor at all, which is why bilateral CTA indemnification clauses are so often the slowest part of contract negotiation. Because of that variability, this entry describes the CTA’s structure and the negotiation questions it raises rather than presenting a fabricated worked-example document — for the one clause that gets the deepest independent treatment on its own, see the indemnity and insurance guide linked above.

Who Negotiates a CTA

At institutions that run a meaningful clinical-trial portfolio, CTA review and negotiation is one of the defining functions of the Clinical Trials Office (CTO), distinct from a general Sponsored Programs Office that administers the institution’s broader grants and contracts portfolio. The CTO typically negotiates the CTA in parallel with per-subject budget development and Medicare Coverage Analysis (billing-compliance review under the Medicare Clinical Trial Policy, NCD 310.1), since the CTA’s payment terms and the coverage analysis have to stay consistent with each other.

Where the CTA Fits in Study Start-Up

Executing the CTA is one of the gating milestones in study start-up, alongside IRB approval, site-specific budget finalization, and site initiation. A trial generally cannot enroll its first subject until the CTA is fully executed. Once the trial is underway, the executed CTA itself becomes an essential document retained in the Trial Master File (TMF), per the TMF Reference Model’s document taxonomy.

A Note on the “CTA” Acronym

“CTA” is genuinely overloaded in clinical-research usage and worth disambiguating explicitly: this entry covers the Clinical Trial Agreement — the sponsor-institution contract. The same three letters also commonly denote a Clinical Trial Associate, a sponsor- or CRO-side administrative-support role, and, in Health Canada’s regulatory system, a Clinical Trial Application — the regulatory filing (governed by the Food and Drug Regulations, Part C, Division 5) that a sponsor must submit and receive a No Objection Letter for before a Phase I-III drug trial can proceed in Canada, structurally analogous to but procedurally distinct from an FDA IND. Confirm which sense a source means from context before assuming.

Related Terms

Machine-readable encodings

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="Clinical Trial Agreement (CTA)"
      vocab-term-identifier="https://casrai.org/dictionary/term/clinical-trial-agreement-cta" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/clinical-trial-agreement-cta",
  "name": "Clinical Trial Agreement (CTA)",
  "identifier": "https://casrai.org/dictionary/term/clinical-trial-agreement-cta",
  "description": "A Clinical Trial Agreement (CTA) is the legally binding contract between a study sponsor (or a Contract Research Organization acting for the sponsor) and the institution/site conducting the trial (and, typically, the Principal Investigator as a party or signatory) that sets the business and legal terms under which the trial will be performed at that site. A document qualifies as a CTA -- as distinct from the protocol, the informed consent form (ICF), or a data/material-transfer agreement -- when it governs the commercial and risk-allocation terms of the relationship rather than the scientific conduct of the study itself: per-subject and milestone budget and payment schedule, indemnification and insurance (including coverage for trial-related subject injury), intellectual property ownership (background vs. foreground), publication and disclosure rights, data ownership and confidentiality, regulatory-compliance representations, and termination and record-retention terms. The protocol defines what will be done scientifically; the ICF discloses risks and obtains a subject's voluntary participation; the CTA is the separate contract that lets the institution and sponsor actually transact -- get paid, allocate liability, and agree who owns and can publish what comes out of the trial.",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
  "url": "https://casrai.org/dictionary/term/clinical-trial-agreement-cta",
  "sameAs": [],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-18T04:21:48",
  "inLanguage": "en"
}